Science

Mar 30, 2025, 13:32

Myeloma Paper of the Day, March 30th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Flatiron health record analysis comparing carfilzomib dosing in relapsed/refractory myeloma finds no support for improved outcomes with 2x weekly dosing; K56-1x may best balance efficacy, safety and avoidance of time toxicity.”

“Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis”

Authors: Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Adam Sperling, Larry Anderson Jr, Vincent Rajkumar, Gurbakhash Kaur et al.

More posts featuring Robert Orlowski.

Adam Sperling Adeel M. Khan cancer Gurbakhash Kaur Larry Anderson Jr Mengru Wang multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Rahul Banerjee Relapsed or Refractory Multiple Myeloma Robert Orlowski RRMM Sharlene Dong Vincent Rajkumar Xiaoliang Wang

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts